K Number
K211678
Device Name
Lunit INSIGHT MMG
Manufacturer
Date Cleared
2021-11-17

(169 days)

Product Code
Regulation Number
892.2090
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
Lunit INSIGHT MMG is a radiological Computer-Assisted Detection and Diagnosis (CADe/x) software device based on an artificial intelligence algorithm intended to aid in the detection, and characterization of suspicious areas for breast cancer on mammograms from compatible FFDM systems. As an adjunctive tool, the device is intended to be viewed by interpreting physicians after completing their initial read. It is not intended as a replacement for a complete physician's review or their clinical judgement that takes into account other relevant information from the image or patient history. Lunit INSIGHT MMG uses screening mammograms of the female population.
Device Description
Lunit INSIGHT MMG is a radiological Computer-Assisted Detection and Diagnosis (CADe/x) software for aiding interpreting physicians with the detection, and characterization of suspicious areas for breast cancer on mammograms from compatible FFDM (full-field digital mammography) systems. The software applies an artificial intelligence algorithm for recognition of suspicious lesions, which are trained with large databases of biopsy proven examples of breast cancer, benign lesions and normal tissues. Lunit INSIGHT MMG automatically analyzes the mammograms received from the client's image storage system (e.g., Picture Archiving and Communication System (PACS)) or other radiological imaging equipment. Following receipt of mammograms, the software device de-identifies the copies of images in DICOM format (.dcm) and then automatically analyzes each image and identifies and characterizes suspicious areas for breast cancer. The analysis result is converted into DICOM file and the result is saved within the designated storage location (e.g., PACS, x-ray system, etc.) Lunit INSIGHT MMG processes mammograms and the output of the device can be viewed by interpreting physicians after completing their initial read. As an analysis result, the software device allows a visualization and quantitative estimation of the presence of a malignant lesion. The suspicious lesions are marked by a visualized map and an abnormality score, which reflects general likelihood of presence of malignancy, is presented for each lesion, as well as for each breast.
More Information

Not Found

Yes
The device description explicitly states that the software applies an "artificial intelligence algorithm" and that the "machine learning components are trained".

No
The device is a diagnostic aid, providing detection and characterization of suspicious areas for breast cancer on mammograms, but it does not treat or cure a disease or condition.

Yes
The "Intended Use / Indications for Use" states that the device is "intended to aid in the detection, and characterization of suspicious areas for breast cancer on mammograms." This directly describes a diagnostic function.

Yes

The device is described as a "software device" that analyzes mammograms received from existing imaging systems (PACS, x-ray systems). It processes digital images and outputs results as a DICOM file, indicating it operates solely on data and does not include or require specific hardware components beyond the existing infrastructure.

Based on the provided information, this device is not an IVD (In Vitro Diagnostic).

Here's why:

  • IVD Definition: In vitro diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections.
  • Device Function: Lunit INSIGHT MMG is a software device that analyzes medical images (mammograms). It does not perform tests on biological samples.
  • Intended Use: The intended use is to aid in the detection and characterization of suspicious areas for breast cancer on mammograms, which are images, not biological samples.
  • Input: The input is FFDM images, not biological specimens.

Therefore, Lunit INSIGHT MMG falls under the category of medical imaging software, specifically a Computer-Assisted Detection and Diagnosis (CADe/x) device, rather than an In Vitro Diagnostic device.

No
The letter does not explicitly state that the FDA has reviewed and approved or cleared a PCCP for this specific device.

Intended Use / Indications for Use

Lunit INSIGHT MMG is a radiological Computer-Assisted Detection and Diagnosis (CADe/x) software device based on an artificial intelligence algorithm intended to aid in the detection, and characterization of suspicious areas for breast cancer on mammograms from compatible FFDM systems. As an adjunctive tool, the device is intended to be viewed by interpreting physicians after completing their initial read.

It is not intended as a replacement for a complete physician's review or their clinical judgement that takes into account other relevant information from the image or patient history. Lunit INSIGHT MMG uses screening mammograms of the female population.

Product codes (comma separated list FDA assigned to the subject device)

QDQ

Device Description

Lunit INSIGHT MMG is a radiological Computer-Assisted Detection and Diagnosis (CADe/x) software for aiding interpreting physicians with the detection, and characterization of suspicious areas for breast cancer on mammograms from compatible FFDM (full-field digital mammography) systems. The software applies an artificial intelligence algorithm for recognition of suspicious lesions, which are trained with large databases of biopsy proven examples of breast cancer, benign lesions and normal tissues.

Lunit INSIGHT MMG automatically analyzes the mammograms received from the client's image storage system (e.g., Picture Archiving and Communication System (PACS)) or other radiological imaging equipment. Following receipt of mammograms, the software device de-identifies the copies of images in DICOM format (.dcm) and then automatically analyzes each image and identifies and characterizes suspicious areas for breast cancer. The analysis result is converted into DICOM file and the result is saved within the designated storage location (e.g., PACS, x-ray system, etc.)

Lunit INSIGHT MMG processes mammograms and the output of the device can be viewed by interpreting physicians after completing their initial read. As an analysis result, the software device allows a visualization and quantitative estimation of the presence of a malignant lesion. The suspicious lesions are marked by a visualized map and an abnormality score, which reflects general likelihood of presence of malignancy, is presented for each lesion, as well as for each breast.

Mentions image processing

Yes

Mentions AI, DNN, or ML

Mentions AI: "based on an artificial intelligence algorithm"
Mentions AI: "The software applies an artificial intelligence algorithm for recognition of suspicious lesions"
Mentions ML: "similar machine learning techniques"
Mentions ML: "The system includes 'deep learning' algorithm applied to images for recognition of suspicious lesions for breast cancer. The machine learning components are trained to detect suspicious lesions for breast cancer with large databases of biopsy-proven cases of breast cancer, benign lesions and normal tissues."

Input Imaging Modality

Screening mammograms from compatible FFDM (full-field digital mammography) systems. FFDM

Anatomical Site

Breast

Indicated Patient Age Range

Not Found. Device uses "screening mammograms of the female population."

Intended User / Care Setting

Interpreting physicians / Not Found.

Description of the training set, sample size, data source, and annotation protocol

...are trained with large databases of biopsy proven examples of breast cancer, benign lesions and normal tissues.

Description of the test set, sample size, data source, and annotation protocol

Standalone Performance Study:
Sample Size: Total of 2412 mammograms
Data Source: collected using Hologic, GE Healthcare, and Siemens mammography equipment.
Annotation protocol: The dataset used in the study is independent from the dataset used for development of the algorithm and the US pivotal reader study.

Clinical Testing - Reader Study:
Sample Size: Total of 240 mammograms
Data source: collected using Hologic and GE Healthcare mammography equipment in the US.
Annotation protocol: During the study, 12 MQSA qualified reading panelists performed their interpretation independently using a setting similar to a screening procedure in the U.S. Reading panelists interpret cases without CAD assistance first then re-interpret of the same cases with Test 1 reading results in assistance of the Lunit INSIGHT MMG. To minimize any potential bias, the reading order for each reading panelists was randomized.

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

Non-clinical performance Data:
Verification tests which consisted of software unit testing and system testing were successfully completed to assure that the software application satisfied the software requirements. Validation testing determining standalone performance of the algorithms in Lunit INSIGHT MMG was also completed successfully.

Standalone Performance Testing:
Study type: Standalone Performance Study
Sample size: 2412 mammograms
AUC: ROC AUC in the standalone performance analysis was 0.903 (95% Cl: 0.889-0.917)
Key results: Statistical significance (p

§ 892.2090 Radiological computer-assisted detection and diagnosis software.

(a)
Identification. A radiological computer-assisted detection and diagnostic software is an image processing device intended to aid in the detection, localization, and characterization of fracture, lesions, or other disease-specific findings on acquired medical images (e.g., radiography, magnetic resonance, computed tomography). The device detects, identifies, and characterizes findings based on features or information extracted from images, and provides information about the presence, location, and characteristics of the findings to the user. The analysis is intended to inform the primary diagnostic and patient management decisions that are made by the clinical user. The device is not intended as a replacement for a complete clinician's review or their clinical judgment that takes into account other relevant information from the image or patient history.(b)
Classification. Class II (special controls). The special controls for this device are:(1) Design verification and validation must include:
(i) A detailed description of the image analysis algorithm, including a description of the algorithm inputs and outputs, each major component or block, how the algorithm and output affects or relates to clinical practice or patient care, and any algorithm limitations.
(ii) A detailed description of pre-specified performance testing protocols and dataset(s) used to assess whether the device will provide improved assisted-read detection and diagnostic performance as intended in the indicated user population(s), and to characterize the standalone device performance for labeling. Performance testing includes standalone test(s), side-by-side comparison(s), and/or a reader study, as applicable.
(iii) Results from standalone performance testing used to characterize the independent performance of the device separate from aided user performance. The performance assessment must be based on appropriate diagnostic accuracy measures (
e.g., receiver operator characteristic plot, sensitivity, specificity, positive and negative predictive values, and diagnostic likelihood ratio). Devices with localization output must include localization accuracy testing as a component of standalone testing. The test dataset must be representative of the typical patient population with enrichment made only to ensure that the test dataset contains a sufficient number of cases from important cohorts (e.g., subsets defined by clinically relevant confounders, effect modifiers, concomitant disease, and subsets defined by image acquisition characteristics) such that the performance estimates and confidence intervals of the device for these individual subsets can be characterized for the intended use population and imaging equipment.(iv) Results from performance testing that demonstrate that the device provides improved assisted-read detection and/or diagnostic performance as intended in the indicated user population(s) when used in accordance with the instructions for use. The reader population must be comprised of the intended user population in terms of clinical training, certification, and years of experience. The performance assessment must be based on appropriate diagnostic accuracy measures (
e.g., receiver operator characteristic plot, sensitivity, specificity, positive and negative predictive values, and diagnostic likelihood ratio). Test datasets must meet the requirements described in paragraph (b)(1)(iii) of this section.(v) Appropriate software documentation, including device hazard analysis, software requirements specification document, software design specification document, traceability analysis, system level test protocol, pass/fail criteria, testing results, and cybersecurity measures.
(2) Labeling must include the following:
(i) A detailed description of the patient population for which the device is indicated for use.
(ii) A detailed description of the device instructions for use, including the intended reading protocol and how the user should interpret the device output.
(iii) A detailed description of the intended user, and any user training materials or programs that address appropriate reading protocols for the device, to ensure that the end user is fully aware of how to interpret and apply the device output.
(iv) A detailed description of the device inputs and outputs.
(v) A detailed description of compatible imaging hardware and imaging protocols.
(vi) Warnings, precautions, and limitations must include situations in which the device may fail or may not operate at its expected performance level (
e.g., poor image quality or for certain subpopulations), as applicable.(vii) A detailed summary of the performance testing, including test methods, dataset characteristics, results, and a summary of sub-analyses on case distributions stratified by relevant confounders, such as anatomical characteristics, patient demographics and medical history, user experience, and imaging equipment.

0

Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services USA logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.

Lunit Inc. % John Smith Partner Hogan Lovells US LLP 555 Thirteenth Street NW Washington, District of Columbia 20004

February 7, 2022

Re: K211678

Trade/Device Name: Lunit INSIGHT MMG Regulation Number: 21 CFR 892.2090 Regulation Name: Radiological computer assisted detection and diagnosis software Regulatory Class: Class II Product Code: QDQ

Dear John Smith:

The Food and Drug Administration (FDA) is sending this letter to notify you of an administrative change related to your previous substantial equivalence (SE) determination letter dated October 7, 2021. Specifically, FDA is updating this SE Letter due to a typographical error in the 510(k) summary as an administrative correction. Specifically the substantial equivalence table contains an additional column, which could trigger a misinterpretation for members of the public.

Please note that the 510(k) submission was not re-reviewed. For questions regarding this letter please contact Jessica Lamb, OHT7: Office of In Vitro Diagnostics and Radiological Health, 301-796-6167, Jessica.Lamb(@fda.hhs.gov.

Sincerely.

Jessica Lamb

Jessica Lamb Assistant Director Division of Radiological Health OHT7: Office of In Vitro Diagnostics and Radiological Health Office of Product Evaluation and Quality Center for Devices and Radiological Health

1

Image /page/1/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.

Lunit Inc. % John J. Smith, M.D., J.D. Partner Hogan Lovells US LLP 555 Thirteenth Street NW WASHINGTON DC 20004

November 17, 2021

Re: K211678

Trade/Device Name: Lunit INSIGHT MMG Regulation Number: 21 CFR 892.2090 Regulation Name: Radiological computer assisted detection and diagnosis software Regulatory Class: Class II Product Code: QDQ Dated: October 7, 2021 Received: October 7, 2021

Dear Dr. Smith:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for

2

devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely.

Jessica Lamb

For

Thalia T. Mills, Ph.D. Director Division of Radiological Health OHT7: Office of In Vitro Diagnostics and Radiological Health Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

3

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Indications for Use

510(k) Number (if known) K211678

Device Name

Lunit INSIGHT MMG Indications for Use (Describe)

Lunit INSIGHT MMG is a radiological Computer-Assisted Detection and Diagnosis (CADe/x) software device based on an artificial intelligence algorithm intended to aid in the detection, and characterization of suspicious areas for breast cancer on mammograms from compatible FFDM systems. As an adjunctive tool, the device is intended to be viewed by interpreting physicians after completing their initial read.

It is not intended as a replacement for a complete physician's review or their clinical judgement that takes into account other relevant information from the image or patient history. Lunit INSIGHT MMG uses screening mammograms of the female population.

区 Prescription Use (Part 21 CFR 801 Subpart D)

_ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response. including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number

4

510(k) Summary

Lunit INSIGHT MMG (K211678)

This 510(k) summary of safety and effectiveness information is prepared in accordance with the requirements of 21 CFR §807.92.

Date Prepared: November 15, 2021

I. SUBMITTER

Manufacturer:

Lunit Inc. 15 Floor, 27 Teheran-ro 2-gil, Gangnam-gu, Seoul, Republic of Korea 06241 Phone +82-2-2138-0827 Fax +82-2-2135-5413

Contact Person:

Joohee Lee Regulatory Affairs Specialist

II. DEVICE

Name of Device: Lunit INSIGHT MMG Common or Usual Name: Lunit INSIGHT MMG Classification Name: Radiological Computer Assisted Detection/Diagnosis Software For Suspicious Lesions For Cancer Classification Regulation: 21 CFR 892.2090 Requlatory Class: II Product Code: QDQ

III. PREDICATE DEVICE

Predicate Device Manufacturer Name: Screenpoint Medical B.V. Device Trade Name: Transpara™ 510(k) Number: K192287

IV. DEVICE DESCRIPTION

Lunit INSIGHT MMG is a radiological Computer-Assisted Detection and Diagnosis (CADe/x) software for aiding interpreting physicians with the detection, and characterization of suspicious areas for breast cancer on mammograms from compatible FFDM (full-field digital mammography) systems. The software applies an artificial intelligence algorithm for recognition of suspicious lesions,

5

which are trained with large databases of biopsy proven examples of breast cancer, benign lesions and normal tissues.

Lunit INSIGHT MMG automatically analyzes the mammograms received from the client's image storage system (e.g., Picture Archiving and Communication System (PACS)) or other radiological imaging equipment. Following receipt of mammograms, the software device de-identifies the copies of images in DICOM format (.dcm) and then automatically analyzes each image and identifies and characterizes suspicious areas for breast cancer. The analysis result is converted into DICOM file and the result is saved within the designated storage location (e.g., PACS, x-ray system, etc.)

Lunit INSIGHT MMG processes mammograms and the output of the device can be viewed by interpreting physicians after completing their initial read. As an analysis result, the software device allows a visualization and quantitative estimation of the presence of a malignant lesion. The suspicious lesions are marked by a visualized map and an abnormality score, which reflects general likelihood of presence of malignancy, is presented for each lesion, as well as for each breast.

V. INDICATIONS FOR USE

Lunit INSIGHT MMG is a radiological Computer-Assisted Detection and Diagnosis (CADe/x) software device based on an artificial intelligence algorithm intended to aid in the detection, and characterization of suspicious areas for breast cancer on mammograms from compatible FFDM systems. As an adjunctive tool, the device is intended to be viewed by interpreting physicians affer completing their initial read.

lt is not intended as a replacement for a complete physician's review or their clinical judgement that takes into account other relevant information from the image or patient history. Lunit INSIGHT MMG uses screening mammograms of the female population.

VI. COMPARISON OF TECHNOLOGICAL CHARACTERSTICS WITH THE PREDICATE DEVICE

The Lunit INSIGHT MMG and the predicate Transpara have the similar indications where both devices are intended to assist a clinical user in the detection, and characterization suspicious areas for breast cancer on mammography images. Also, both devices have intended user, and patient populations, and use the same imaging modality. The differences in the indications are with respect to the clinical workflow where the predicate device is intended to be used for concurrent read of images while the Lunit INSIGHT MMG is intended to be viewed by interpreting physicians after completing their initial read. Neither device is intended as a replacement for the review of a clinician or their clinical judgement and the patient management decisions are not made solely on the basis of analysis of the device. The minor difference in the indications with respect to the clinical workflow does not raise different questions of safety or effectiveness.

Lunit INSIGHT MMG and predicate share similar technological characteristics. Both devices are radiological computer assisted detection and diagnostic software based on an artificial intelligence algorithm that detect, identify and characterize findings based on features or information extracted from images. Both devices provide information about the presence and location of the findings to the user. As both devices process radiological images using similar machine learning techniques to

6

highlight abnormalities, the same types of safety and effectiveness questions are raised between devices. Both devices are support tools that provide relevant clinical data as an additional resource to the physician and will not replace the clinical expertise and judgement of the clinical user.

Both devices provide users with a numeric score indicating the likelihood of a presence of a malignant lesion however, the scoring system is different. Both devices provide a lesion score indicating likelihood of presence of malignancy. Lunit INSIGHT MMG analyzes per-breast abnormality score that takes the maximum scores from two views (i.e. CC, MLO). However, the predicate device analyzes the overall likelihood that cancer is present in a mammogram and categorizes the exams on a scale of 1 to 10 with increasing likelihood of cancer. The minor differences do not raise any different questions for its performance or safety; both devices provide clinically useful information to physicians who are reviewing a mammogram.

A comparison of the technological characteristics with the predicate device is summarized in Table 1.

VII. PERFORMANCE DATA

Non-clinical performance Data

The Lunit INSIGHT MMG is considered as a "moderate" level of concern, since a failure or a latent design flaw of the software device could result in Minor injury, either to a patient or to a user of the device. Based on results of verification and validation tests, Lunit INSIGHT MMG is effective in the detection of suspicious lesion for breast cancer at an appropriate safety level in mammograms. Verification tests which consisted of software unit testing and system testing were successfully completed to assure that the software application satisfied the software requirements. Validation testing determining standalone performance of the algorithms in Lunit INSIGHT MMG was also completed successfully. Validation and verification test results demonstrated that Lunit INSIGHT MMG is as safe and effective as the predicate device.

7

Standalone Performance Testing

Standalone Performance Study of the Lunit INSIGHT MMG assessed the performance of software algorithm for breast cancer detection in screening mammography.

Total of 2412 mammograms were collected using Hologic, GE Healthcare, and Siemens mammography equipment. The standalone performance of Lunit INSIGHT MMG for breast cancer detection in screening mammography is examined as comparing the reference standards and the analysis results of the device. The dataset used in the study is independent from the dataset used for development of the algorithm and the US pivotal reader study.

The primary endpoint of the standalone performance measured the Lunit INSIGHT MMG performance compared to radiologist performance alone. ROC AUC in the standalone performance analysis was 0.903 (95% Cl: 0.889-0.917) with statistical significance (p